Frank Dolan Founder of ARSENAL ADVISORS
Linkedin
Contact

Clubhouse App: @frankdolan

Frank F. Dolan

Founder

Frank has spent over twenty years in biopharmaceuticals serving in commercial leadership roles. At Takeda, Amylin, and Acadia Pharmaceuticals he was a founding member of the team that brought them from R&D-only into launch-ready commercial organizations. His 15 product launches include large market brands such as Lipitor to orphan drug portfolios. 

Frank’s strong record of increasing company value has resulted in company acquisitions of over $100 billion.

2019 & 2020: LinkedIn ranked Top 1% in Biotech

Featured Media

Video Interviews

Podcast Interviews on Life Science Marketing Radio

How Does a New Biotech Company Successfully Launch Its First Product?

LSMR.Mainlogo

Elevating Innovation and Trust in Life Science

LSMR.Mainlogo

Past Employers

Diverse Commercial Leadership Experience

Award Winning Brands

History of Brand Impact Recognized by Industry Associations & Press
Previous
Next

Select Publications

Commercialization Of Biologics: Benchmarking Leading Players

5 Keys to Successful Sales Force Integration Post-Merger

Customer Experience (CX) in Physician and HCP Engagement

Contact Us

How May We Help You

Thank you for your interest

ARSENAL ADVISORS is committed to protecting your information. Your information will be used in accordance with the applicable data privacy law, our internal policies and our Privacy Policy. As ARSENAL ADVISORS is a global organization, your information may be stored and processed by ARSENAL ADVISORS and its affiliates in countries outside your country of residence, but wherever your information is processed, we will handle it with the same care and respect for your privacy.

We use cookies essential for this site to function well. Please click “Accept” to help us improve its usefulness with additional cookies. Learn about our use of cookies, and collaboration with select social media and trusted analytics partners in our Terms of Use.​

ACCEPT AND CLOSE
DECLINE